Drug Database
Back to search

Poland· PL-100408146

Biktarvy

A emtricitabine, tenofovir alafenamide and bictegravir product containing bictegravirum natricum + emtricitabinum + tenofovirum alafenamidum fumaras, registered in Poland by Gilead Sciences Ireland UC. The same ATC class is registered in 13 of our 19 countries.

ATC J05AR20

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBiktarvyATCJ05AR20REGISTER NO.PL-100408146PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about bictegravirum natricum + emtricitabinum + tenofovirum alafenamidum fumarasAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Emtricitabine, tenofovir alafenamide and bictegravir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AR20 (emtricitabine, tenofovir alafenamide and bictegravir), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search emtricitabine, tenofovir alafenamide and bictegravir products by name

Emtricitabine, tenofovir alafenamide and bictegravir · ATC J05AR20

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Bictegravirum natricum + Emtricitabinum + Tenofovirum alafenamidum fumaras
Manufacturer
Gilead Sciences Ireland UC
Country
Poland (PL)
ATC code
J05AR20
ATC class
Emtricitabine, tenofovir alafenamide and bictegravir
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05391507144973

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Emtricitabine, tenofovir alafenamide and bictegravir in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All emtricitabine, tenofovir alafenamide and bictegravir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Biktarvy
  • Liechtenstein · Biktarvy
  • Norway · Biktarvy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8303df7c-28ac-4a49-bb28-242407be2343
GET /v1/drugs/8303df7c-28ac-4a49-bb28-242407be2343?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "50 mg + 200 mg + 25 mg",
  "packaging": "05391507144973 ¦ Rpz ¦ EU/1/18/1289 /001 ¦ 129010\n30 tabl.\nRpz ¦ EU/1/18/1289 /002 ¦ 129011\n90 tabl. (3 x 30)\nRpz ¦ EU/1/18/1289/003 ¦ 148504\n30 tabl.\nRpz ¦ EU/1/18/1289/004 ¦ 148505\n90 tabl. (3x30)",
  "substance": "Bictegravirum 50 mg + Emtricitabinum 200 mg + Tenofovirum alafenamidum 25 mg",
  "common_name": "Bictegravirum natricum + Emtricitabinum + Tenofovirum alafenamidum fumaras",
  "pl_product_id": "100408146",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about emtricitabine, tenofovir alafenamide and bictegravir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console